Kemwell Biopharma

The entry if new biosimilars in the market will not only reduce prices but also increase competition. This new development will help patients get access to innovative medication. However, regulatory burdens and high manufacturing costs make it difficult for biosimilar contract manufacturers to reduce prices to the same extent as generics. On the other hand, there is apprehension among biosimilar manufacturers that reducing prices significantly will eliminate the incentive for them to enter the biosimilar space. Addressing these difficulties presents an opportunity to lower drug costs and improve patient access. What’s the Current Practice? For outpatients, reimbursement for medicines administered by providers is based on the Average Sales Price. Medicare pays the provider Average Sales Price + 6% of the medicine. Due to the lag between published Average Sales Price data and product launch, payers depend on Wholesale Acquisition Cost until the Average Sales Pric...

These days,    the diseases are increasing rapidly and there are numerous patients in the world who are waiting for the high quality of medicinal treatment. Due to the growth of the diseases, the dependency on drugs and biologics is increasing and that’s why it has become important that ensure that proper quality of the drug manufacturing procedure. Vaccinations’ and biological drugs are basically manufactured with high-quality proteins in the living organisms but one can say that this procedure isn’t totally reliable. Proteins productions can’t be always accurate and that’s why these can be also ineffective on the targets. There is another problem which is that if the cells aren’t able to produce the right amount of protein, then it would be beneficial for the patient. When there are diseases spreading all over the world, the Contract Manufacturing organizations might be forced to produce high quality of medicines for meeting demands of the affected patients and t...

Do you know that technology in CMO industries is increasing at a rapid pace? This enhancement in technology is helping the number of biotechnology and pharmaceutical companies to develop drugs on large scale production. You can hire the CMO for the small quantity medicines for clinical studies and R&D procedures. Most of the medicines manufactured with the help of CMOs are available in liquid or solid form which can also be injected properly.   There are lots of advantages of pharmaceutical contract manufacturing and here are some of them. ·          High-quality work During the production of the drug, the most important thing is its quality. If the quality isn’t assured, then it can ruin the life of lots of people. The Contract manufacturing companies are already established and that’s why these companies can help in manufacturing high standards of medicines to meet the requirement of a number of countries. The quality o...

Do you know the role of automation in cell line development? The enhanced speed provides better quality, efficiency, and speed to the drug market. For a biopharmaceutical production company, the automated cell line has become really important but with the manual procedures, it can take a lot of time and difficult working tasks. The process can speed up using automated development and then the technicians can focus on the other important tasks they need to do. The date and timing of the cell growth can be scheduled according to the cell types. This helps the researchers to know the time when cells can be available for research projects. The certain factors which can limit the productivity in the automated process are the time required for assays, sub-clone of cells, maintenance and automation of cell-based protocols. There are a lot of automated platforms which are useful for reducing costs during the production of biopharmaceutical production. In the automated system, the...

As the APIs are becoming more and more complex, the demand for contract manufacturing is increasing. Most of the biopharmaceutical companies depend on CDMOs and contract development services in order to produce safe and high quality of sterile drugs. The demand for sterile fill finish is increasing and that’s why its manufacturing has become quite important. Specialized equipment and capabilities are necessary for completing complicated tasks. Due to various challenges in the production of these drugs, most of the companies depend on CDMOs in order to manage the proper manufacture of drugs. The smaller companies without any production capabilities depend on the outsourcing partners. Whenever the specialized capabilities are required, then the large companies take the help of contract manufacturing companies. One can definitely believe that CDMOs are a backup source for drug manufacturing companies. It is necessary for the drug pharmaceutical companies to choose the best pa...

Since the past few years, the protein therapeutics are the growth drivers of most of the biopharmaceutical companies. Some of the monoclonal antibody products are able to become one of the best selling medicines in the world. It has become quite challenging to produce biotherapeutics due to its complex and large sized molecules . Due to its fragile nature, manufacturers are forced to change the way they used to handle drug products earlier. The market of biologics is increasing during the past decade and the sales have been increased up to 20%. The living sources are used to extract drugs in case of biopharmaceutical drugs. Cells, nucleic acids, viruses, vaccines are some of the products which are used for the manufacture of these drugs . It might not be much difficult to carry on the production of biologics but these are expensive. Due to complex chains , it carries a lot of cost during the manufacture of these drugs.    The structure of the prot...